Sir Andrew Witty, the former long-serving chief executive of UK drugmaker GlaxoSmithKline, has jumped into the biotech venture-capital sector, joining Hatteras Venture Partners.
Sir Andrew is joining US-based Hatteras as a venture partner. Separately, GSK’s ex-research and development head Moncef Slaoui has joined European venture firm Medicxi.
